Pajjiż: Stati Uniti
Lingwa: Ingliż
Sors: NLM (National Library of Medicine)
BETAINE (UNII: 3SCV180C9W) (BETAINE - UNII:3SCV180C9W)
Recordati Rare Diseases
BETAINE
BETAINE 1 g in 1 g
ORAL
PRESCRIPTION DRUG
CYSTADANE ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: - Cystathionine beta-synthase (CBS) deficiency - 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency - Cobalamin cofactor metabolism (cbl) defect None. Risk Summary Available data from a limited number of published case reports and postmarketing experience with CYSTADANE use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with betaine. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc
CYSTADANE is available in plastic bottles containing 180 grams of betaine anhydrous as a white, granular, hygroscopic powder. Each bottle is equipped with a plastic child-resistant cap and is supplied with a polypropylene measuring scoop. One level scoop (1.7 mL) is equal to 1 gram of betaine anhydrous powder. NDC 52276-400-01 180 g/bottle Store at room temperature, 15 to 30 ˚C (59 to 86 ˚F). Protect from moisture.
New Drug Application
CYSTADANE- BETAINE POWDER, FOR SOLUTION RECORDATI RARE DISEASES ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CYSTADANE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CYSTADANE. CYSTADANE (BETAINE ANHYDROUS FOR ORAL SOLUTION) POWDER INITIAL U.S. APPROVAL: 1996 INDICATIONS AND USAGE CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are ( 1): Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect DOSAGE AND ADMINISTRATION Adults and Pediatric Patients 3 Years of Age and Older The recommended dosage is 6 grams per day, administered orally in divided doses of 3 grams twice daily. ( 2.1) Pediatric Patients Less than 3 Years of Age The recommended starting dosage is 100 mg/kg/day, administered orally in divided doses of 50 mg/kg twice daily, and then increased weekly by 50 mg/kg increments. ( 2.1) Monitor patient response by plasma homocysteine concentrations. ( 2.1) Increase the dosage gradually until the plasma total homocysteine concentration is undetectable or present only in small amounts. ( 2.1) Preparation and Adminstration Instructions Prescribed amount of CYSTADANE should be measured with the measuring scoop provided and then dissolved in 4 to 6 ounces of water, juice, milk, or formula until completely dissolved, or mixed with food for immediate ingestion. ( 2.2) DOSAGE FORMS AND STRENGTHS For oral solution: in bottles containing 180 grams of betaine anhydrous. ( 3) CONTRAINDICATIONS None ( 4) WARNINGS AND PRECAUTIONS Hypermethioninemia in Patients with CBS Deficiency: CYSTADANE may worsen elevated plasma methionine concentrations and cerebral edema has been reported. Monitor plasma methionine concentrations in patients with CBS deficiency. Keep plasma methionine concentration Aqra d-dokument sħiħ